Invitae Launches $160M Common Stock Offering; Expects 55 Percent Q1 Revenue Increase

Apr 02, 2020

|

NEW YORK – Invitae announced Wednesday evening that it has priced a $160 million public offering of 17,777,778 shares of common stock.

The offering was priced at $9.00 per share and is slated to close on April 6. Invitae is also granting underwriters a 30-day option to purchase an additional 2,666,666 shares of common stock at the same price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Stricter Vaccine Standards

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Another Trial to Ramp Up

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Few Billion More

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Menu

Invitae Launches $160M Common Stock Offering; Expects 55 Percent Q1 Revenue Increase

To read the full story....

Breaking News

CRISPR Screen Uncovers Genes That Help Cancer Cells Evade Immune System

Pale Melanoma Susceptibility Linked to Albinism-Related Genes

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Metabolon Closes $72M in Debt and Equity Funding

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

The Scan

Stricter Vaccine Standards

Another Trial to Ramp Up

Few Billion More

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

What's Popular?

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Metabolon Closes $72M in Debt and Equity Funding

Illumina to Acquire Grail for $8B in Cash and Stock

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

Sponsorships